Clinical efficacy and safety of Pamidronate therapy on bone mass density in early post-renal transpl

• 作 者: Wang Zijie Han Zhijian Tao Jun Lu Pei Liu Xuzhong Wang Jun Wu Bian Huang Zhengkai Yin Changjun Tan Ruoyun Gu Min
• 机 构: Department of urology,the first affiliated hospital of Nanjing Medical University,210029
• 出 处: 江苏省第十五次泌尿外科学学术会议
• 发表日期: 2014年11期

Objectives The overall effect of pamidronate on bone mass density (BMD) in the early renal transplant period varies considerably among studies.The effects of pamidronate on graft function have not been determined.Methods A comprehensive search was conducted in PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (updated on December 15th 2013) independently by two authors (Wang and Han).Randomized controlled trials of pamidronate evaluating bone loss in the first year of renal transplantation were included.Methods reported in the "Cochrane Handbook for Systematic Reviews of Interventions 5.0.2" were used to evaluate changes of lumbar spine and femoral neck BMD, and serum creatinine, calcium and intact parathyroid hormone (iPTH) levels.Fixed or random effect models were used as appropriate.